J.P. Morgan analyst Anupam Rama has maintained their bullish stance on APLS stock, giving a Buy rating on October 31. Anupam Rama has given ...

Scotiabank initiated coverage on shares of Apellis Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector ...

In October 2024, we announced the appointment of Jason L ... where he oversaw the successful launch of SYFOVRE ®, the first treatment approved for geographic atrophy (GA). In his new role, Mr.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eighteen analysts that are currently covering the firm, MarketBeat ...

Oct. 16, 2024 (GLOBE NEWSWIRE ... and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the ...

Oct. 16, 2024 (GLOBE NEWSWIRE ... and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch ...

Oct. 16, 2024 (GLOBE NEWSWIRE ... and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the ...

Derek Archila, an analyst from Wells Fargo, maintained the Hold rating on Apellis Pharmaceuticals (APLS – Research Report). The ...

Avacincaptad pegol was scheduled to be reviewed at the CHMP's October meeting ... which the drugmaker claims differentiates it from Syfovre. "GA is a devastating progressive disease, which ...